MMP-13 inhibitors

Abstract

Aventis Research & Technology claim in two separate applications, two distinct chemotypes that are matrix metalloproteinase (MMP) inhibitors, selective or partially selective, for MMP-13. The compounds are claimed to be useful in the treatment of osteoarthritis, connective tissue and bone diseases, and cancer. N-Arylsulfonyl 2-hydroxyaminocarbonyl octahydro-indole and octahydro-cyclopenta[b]pyrrole derivatives are stated to also have high selectivity for MMP-2, MMP-3, MMP-8 and MMP-9 whilst sparing MMP-1. N,N’-bisaryl-pyrimidine-4,6-dicarboxamide derivatives are indicated to be much more selective for MMP-13, especially with respect to MMP-3 and MMP-8, and are claimed to be useful for the same indications.

• collagenase
• matrix metalloproteinase
• MMP-13
• MMP inhibitor
• N-hydroxamic acid
• osteoarthritis
• pyrimidine-4,6-dicarboxamide
• sulphonamide